LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

LLY

1,067.68

+0.83%↑

JNJ

205.97

+1.01%↑

ABBV

229.49

-2.82%↓

UNH

318.47

-0.28%↓

AZN

91.56

+0.6%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

17.04 0.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.55

Max

17.28

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

106.172

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-5.88% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.31%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-9.6M

342M

Iepriekšējā atvēršanas cena

16.75

Iepriekšējā slēgšanas cena

17.04

Ziņu noskaņojums

By Acuity

24%

76%

151 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. nov. 21:54 UTC

Iegādes, apvienošanās, pārņemšana

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175 Million

2025. g. 24. nov. 18:26 UTC

Galvenie tirgus virzītāji

Tegna Shares Fall After Trump Blasts Proposal to Lift Broadcast Ownership Cap

2025. g. 24. nov. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Tech Recovery on Wall Street -- Market Talk

2025. g. 24. nov. 23:08 UTC

Tirgus saruna

More Losses Ahead for Steel & Tube, Says New Bear -- Market Talk

2025. g. 24. nov. 23:08 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 24. nov. 22:56 UTC

Tirgus saruna
Peļņas

Alimentation Couche-Tard U.S. Sales Gain Momentum -- Market Talk

2025. g. 24. nov. 22:47 UTC

Tirgus saruna

Kiwi Property Can Keep Growing Its Dividend -- Market Talk

2025. g. 24. nov. 22:36 UTC

Tirgus saruna
Peļņas

Kiwi Property's 1H Result Cements Bull's Confidence in Outlook -- Market Talk

2025. g. 24. nov. 22:32 UTC

Peļņas

Webco Industries 1Q EPS $6.79 >WEBC

2025. g. 24. nov. 22:07 UTC

Peļņas

Couche-Tard 2Q Canada Same-Store Merchandise Revenues Up 5.4% >ATD.T

2025. g. 24. nov. 22:07 UTC

Peļņas

Couche-Tard 2Q U.S. Same-Store Merchandise Revenues Up 1.2% >ATD.T

2025. g. 24. nov. 22:06 UTC

Peļņas

Couche-Tard 2Q Adj EPS 78c >ATD.T

2025. g. 24. nov. 22:06 UTC

Peļņas

Couche-Tard 2Q Rev $17.9B >ATD.T

2025. g. 24. nov. 22:06 UTC

Peļņas

Couche-Tard 2Q EPS 79c >ATD.T

2025. g. 24. nov. 22:05 UTC

Peļņas

Couche-Tard 2Q Rev $17.9B >ATD.T

2025. g. 24. nov. 22:05 UTC

Peļņas

Couche-Tard 2Q Net $740.6M >ATD.T

2025. g. 24. nov. 22:05 UTC

Peļņas

Couche-Tard 2Q Adj EPS 78c >ATD.T

2025. g. 24. nov. 22:05 UTC

Peļņas

Couche-Tard 2Q EPS 79c >ATD.T

2025. g. 24. nov. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2025. g. 24. nov. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 24. nov. 21:44 UTC

Tirgus saruna

Canada Close to MOU With Alberta About New Possible Pipeline -- Market Talk

2025. g. 24. nov. 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Exodus Agrees to Acquire W3C Corp in Deal Valued at $175M

2025. g. 24. nov. 20:42 UTC

Tirgus saruna

Oil Futures Snap Three-Session Losing Streak -- Market Talk

2025. g. 24. nov. 20:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 24. nov. 19:56 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Says It's Not Enron in Private Memo Refuting Accounting Questions -- Barrons.com

2025. g. 24. nov. 18:26 UTC

Tirgus saruna

Crude Futures Move Higher in Choppy Trade -- Market Talk

2025. g. 24. nov. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2025. g. 24. nov. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 24. nov. 17:09 UTC

Tirgus saruna

Brent Could Drop to the $30s Without Production Cuts, JPM Says -- Market Talk

2025. g. 24. nov. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

Strategy Silent on Bitcoin Holdings. Why It's a Big Deal for the Stock and Cryptos. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-5.88% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -5.88%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

151 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat